MediciNova, Inc.

MNOV Healthcare Biotechnology

MediciNova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $409,700.00, down 59.0% from fiscal 2023. In the quarter to June 2026, revenue grew 240.6%, EPS grew 28.6% and free cash flow grew 16.8%, each against the same quarter a year earlier.

1.42 0.03 −2.07%
Market cap
$71.4M
P/E
0.0×
Fwd P/E
−5.0×
Dividend yield
—
F-score
n/a
Altman Z
−4.10
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
70.59 113.03 45.60 48.08
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(33.84) (19.43) (31.87) (36.57)
P/B ratio
1.74 1.71 1.55 1.42
Price to Tangible BV
2.35 2.26 2.01 1.81
EV/Sales
42.98 67.22 23.74 22.95
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
(4.34) (4.22) (3.41) (3.06)
EV/FCF
(4.34) (4.22) (3.41) (3.06)
Quick Ratio
8.58 8.91 8.11 9.76
Current Ratio
8.75 9.09 8.16 9.86
Net Debt/EBITDA
10.02 9.65 9.98 9.65
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.02 0.01 0.03 0.02
Operating CF/Net income
0.83 1.34 0.72 0.56
Capex/Depreciation
0.00 (2.51) 0.00 (0.55)
Research and Development Expense of Revenue
224.52% 675.13% 1,017.40% 1,283.86%
Selling, General and Administrative Expense of Revenue
399.17% 850.37% 1,024.19% 1,464.80%
Intangible Assets out of Total Assets
0.24 0.22 0.21 0.20
Share Based Compensation of Revenue
38.55% 218.07% 119.05% 127.90%
Graham Net Nets
0.35 0.37 0.42 0.47
Graham Number
0.00 0.00 0.00 0.00
Earnings Yield
(15.91%) (16.79%) (18.32%) (19.69%)
Free Cash Flow Yield
(14.04%) (14.10%) (15.27%) (15.62%)
Revenue per Share
0.01 0.00 0.00 0.00
Operating CF per Share
(0.04) (0.07) (0.04) (0.03)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.04) (0.07) (0.04) (0.03)
Cash per Share
0.52 0.56 0.63 0.66
Shareholders Equity per Share
0.76 0.80 0.85 0.90
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
0.76 0.80 0.85 0.90
Free Cash Flow
(1.92) (3.48) (2.02) (1.71)
Working Capital
22.96 25.05 27.19 29.59
Capital Expenditures
0.00 (0.01) 0.00 0.00
Net Current Asset Value
22.76 24.85 26.97 29.31
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.06 0.00 0.02
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Payables
0.76 0.79 0.86 0.73
Average Assets
45.13 47.57 50.74 52.85
Average Common Equity
42.06 44.67 47.05 49.52

Fold the line items

Columns are period end dates